Treatment-related adverse events of combined anti-angiogenic and immune checkpoint inhibitors:systematic review and meta-analysis  

作　　者：Lian Chen Ling Wu Zhang Lu Qin Huang Liu Huang 

机构地区：[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China [2]Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China

出　　处：《Oncology and Translational Medicine》2022年第6期301-310,共10页肿瘤学与转化医学（英文版）

摘　　要：Objective Immune checkpoint inhibitor(ICI)plus angiogenesis inhibitor(AI)combination therapy is a novel treatment model for multiple cancers that normalizes vascular-immune crosstalk to potentiate cancer immunity.In this review,we summarize the characteristics of adverse effects(AEs)and all fatal cases reported in clinical studies involing ICI+AI therapy.Methods Four databases were systematically searched for eligible studies,and 28 relevant studies were selected for inclusion.Results Of the patients included,58.1%developed grade≥3 AEs.The most common fatal AEs were cardiovascular events,severe infections,and hemorrhage.Compared with AI alone,ICI+AI therapy resulted in more cases of grade≥3 proteinuria,liver injury,and fatal AEs(2.49%vs.1.28%,P=0.0041),especially respiratory toxicities and severe infections;however,ICI+AI therapy reduced hematological toxicity.Conclusion We shared comprehensive and practical safety data to review the adverse events associated with ICI+AI treatment.

关 键 词：combination therapy immune checkpoint inhibitor angiogenesis inhibitor treatment-related adverse events systematic review META-ANALYSIS 

分 类 号：R730.51[医药卫生—肿瘤]